Protagonist Therapeutics Inc [PTGX] stock is trading at $30.43, up 2.84%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PTGX shares have gain 13.63% over the last week, with a monthly amount glided 14.31%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, February 2024, Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update. In a post published today on Yahoo Finance, Worldwide collaboration agreement executed with Takeda Pharmaceuticals, including a $300 million upfront payment for rusfertide in polycythemia vera and other hematological indications.
From an analyst’s perspective:
Protagonist Therapeutics Inc [NASDAQ: PTGX] stock has seen the most recent analyst activity on October 30, 2023, when CapitalOne initiated its Overweight rating and assigned the stock a price target of $32. On August 25, 2022, JMP Securities initiated with a Mkt Outperform rating and assigned a price target of $21 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $55 on February 11, 2022. JP Morgan upgraded its rating to a Overweight and raised its price target to $55 on October 12, 2021. Northland Capital upgraded its rating to Outperform for this stock on October 11, 2021, but kept the price target unchanged to $40. In a note dated September 20, 2021, JP Morgan downgraded an Neutral rating on this stock and revised its target price from $60 to $49.
Protagonist Therapeutics Inc [PTGX] stock has fluctuated between $13.72 and $30.10 over the past year. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Protagonist Therapeutics Inc [NASDAQ: PTGX] shares were valued at $30.43 at the most recent close of the market. An investor can expect a potential return of 15.02% based on the average PTGX price forecast.
Analyzing the PTGX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is 0.37 and Total Capital is -0.51. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 29.59 points at the first support level, and at 28.76 for the second support level. However, for the 1st resistance point, the stock is sitting at 31.33, and for the 2nd resistance point, it is at 32.24.
Protagonist Therapeutics Inc [PTGX] reported earnings per share of -$0.58 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.69/share, meaning a difference of $0.11 and a surprise factor of 15.90%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.68 per share as compared to estimates of -$0.65 per share, a difference of -$0.03 representing a surprise of -4.60%.
Ratios To Look Out For
For context, Protagonist Therapeutics Inc’s Current Ratio is 16.71. In addition, the Quick Ratio stands at 16.71 and the Cash Ratio stands at 8.27. Considering the valuation of this stock, the price to sales ratio is 29.25, the price to book ratio is 5.22.
Transactions by insiders
Recent insider trading involved Gupta Suneel, Chief Development Officer, that happened on Jan 09 when 5000.0 shares were sold. President and CEO, PATEL DINESH V PH D completed a deal on Dec 13 to sell 75000.0 shares. Meanwhile, Chief Medical Officer MOLINA ARTURO MD sold 1848.0 shares on Nov 15.
